Growth hormone secretagogue
Ipamorelin
A synthetic pentapeptide with no approved drug product. Of the compounds in this library, it is the one currently placed in FDA's active Category 2 for bulk substances used in compounding.
Also listed as: NNC 26-0161, Ipamorelin acetate
Chemical identity
- Compound class
- Growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist. Synthetic pentapeptide containing unnatural amino acids
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Molecular formula
- C38H49N9O5
- Molecular weight
- 711.9 g/mol
- CAS number
- 170851-70-4
- PubChem CID
- 9831659
- Research categories
- Growth hormone secretagogues
United States regulatory status
FDA compounding Category 2
- No approved drug product exists in Drugs@FDA.
- Ipamorelin acetate is on FDA's active 503B Category 2 table, added 29 September 2023 — bulk drug substances that may present significant safety risks when used in compounding.
- FDA's published concerns include immunogenicity risk from aggregation and impurities, and the difficulty of characterising an API containing unnatural amino acids.
- A separate 503A nomination was withdrawn by the nominator.
Anti-doping status
Named at S2.2.4 among growth hormone secretagogues. Prohibited at all times; non-Specified.
Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.
Sources
Last reviewed 3 September 2026 · Compiled by Therapept Editorial · How these records are built